
First use of click chemistry in CAR-T cell therapy shows promise
Acepodia has announced promising preliminary data from its Phase I dose escalation clinical trial of ACE1831, an anti-CD20 antibody conjugated allogeneic gamma delta T cell therapy being evaluated in patients with non-Hodgkin’s lymphoma (NHL). One out of five patients demonstrated complete response (CR) and three out… Read More
